Research programme: growth factor modulators - Scholar Rock

Drug Profile

Research programme: growth factor modulators - Scholar Rock

Alternative Names: Niche modulators - Scholar Rock; SRK 015

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scholar Rock
  • Class Antifibrotics; Antineoplastics
  • Mechanism of Action Bone morphogenetic protein receptor antagonists; Myostatin inhibitors; TGF-beta superfamily protein inhibitors; TGF-beta superfamily protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia; Autoimmune disorders; Fibrosis; Musculoskeletal disorders; Spinal cord injuries; Spinal muscular atrophy

Most Recent Events

  • 29 Mar 2018 SRK 015 receives Orphan Drug status for Spinal muscular atrophy in USA
  • 06 Feb 2018 Pharmacodynamics data from a preclinical trial in Spinal muscular atrophy released by Scholar Rock
  • 03 Jan 2018 Scholar Rock plans a phase I trial of SRK 015 for Spinal muscular atrophy, in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top